Archive for the ‘Lyme’ Category

Chronic Lyme Disease Patients Want to Be Treated, Not “Managed” By Physicians

https://danielcameronmd.com/recommendations-to-clinicians-on-how-to-handle-chronic-lyme-disease-patients/

CHRONIC LYME DISEASE PATIENTS WANT TO BE TREATED, NOT ‘MANAGED’ BY PHYSICIANS

Over the past month, a series of articles, focusing on multiple aspects of Lyme disease, from pediatric Lyme to chronic Lyme to life after Lyme, have been published in the May and June issues of Infectious Disease Clinics of North America and Clinical Infectious Diseases. The articles echo messages that, for the most part, minimize a disease that impacts hundreds of thousands of people each year — many of whom are children.

“Minds are like parachutes. They only function when open.” This particular quote by Thomas Dewar came to mind after reading an article, Chronic Lyme Disease (1) in the June issue of Infectious Disease Clinics of North America.

In it, the author writes, “the scientific community has largely rejected chronic, treatment-refractory Borrelia burgdorferi infection.” This is based on “the failure to detect cultivatable, clinically relevant organisms after standard treatment.”

The intention of the Chronic Lyme Disease article is evident — convince readers that chronic Lyme disease does not exist, and that antibiotics prescribed for more than 14- to 28-days are of no benefit and most patients have no lingering symptoms.

It is particularly troublesome that the author, Paul Lantos, MD, a Duke University Medical Center researcher, is co-chair on a panel responsible for updating the Infectious Disease Society of America’s (IDSA) treatment guidelines for Lyme disease. Dr. Lantos holds a position not to be taken lightly. The IDSA recommendations will determine, for the most part, the types of treatment patients diagnosed with Lyme disease will receive.

Additionally, Dr. Lantos includes a section entitled, “Clinical Approach to Patients with Chronic Lyme Disease Diagnosis,” in which he offers suggestions to physicians on how to ‘manage’ patients complaining they have chronic Lyme disease. Recommendations include listening patiently during the consultation and then explaining to the patient why their symptoms are not related to Lyme disease.

“…a certain amount of time must be spent reviewing past experiences and past laboratory tests … then explaining why Lyme disease may not account for their illnesses.”

“Even if chronic Lyme disease lacks biological legitimacy, its importance as a phenomenon can be monumental to the individual patient,” says Lantos. “Many have undergone frustrating, expensive, and ultimately fruitless medical evaluations. And many have become quite disaffected with a medical system that has failed to provide answers.”

Managing patients, who insist they have chronic Lyme disease can be challenging, he warns. This subset of patients can have “great variation in their ‘commitment’ to a chronic Lyme disease diagnosis. Some patients are entirely convinced they have chronic Lyme disease, they request specific types of therapy, and they are not interested in adjudicating the chronic Lyme disease diagnosis.”

Should a clinician have a patient who believes they have chronic Lyme disease, there are several ways to manage the evaluation, he explains. First, “the physician needs to suppress preconceptions or biases about such patients.”

Second, “the process of clinical information gathering in medicine … is no different in the context of chronic Lyme disease. Even if much discussion is centered on chronic Lyme disease.”

And, lastly, “it is of utmost importance to not seem to be impatient, dismissive, or rushed. Many patients who seek care for chronic Lyme disease already have accumulated frustration. … Each patient’s clinical story and personal history is unique and valid, even if one concludes that they do not have Lyme disease.”

For the patients who do remain chronically symptomatic, Dr. Lantos explains, there has been “little evidence of active infection, and their symptoms do not respond to antibiotics any better than to placebo.”

When dealing with complex, chronic illnesses, physicians need to develop a trusting and understanding relationship with their patients. It is impossible for a clinician to provide the highest level of care to their patients, which includes a thorough evaluation, if they enter into the doctor-patient relationship with preconceived notions, not only about an extremely complex disease but about the patient who is reporting the symptoms, which are often subjective.

Should the patient not have any of the three objective signs of Lyme disease — the bulls-eye rash, swollen knee and/or Bell’s Palsy, identifying the infection is dependent on a strong evaluation. Patients want physicians to provide effective treatments. They don’t want to be ‘managed.’

It is time for a new narrative. One that recognizes the complexity of the Lyme spirochete and acknowledges the ineffective simplicity of the ‘one-size fits all’ treatment approach.

References:

  1. Lantos PM. Chronic Lyme Disease. Infect Dis Clin North Am, 29(2), 325-340 (2015).

___________________

**Comment**

Lantos is obviously unaware of this which showed a 70% complete remission of symptoms:   https://madisonarealymesupportgroup.com/2023/07/24/paralyzed-by-lyme-they-were-helped-with-combo-treatments/

Also, it’s imperative to point out that coinfections are rarely taken into consideration, yet chronically infected patients are notoriously coinfected with other pathogens.  The fact they don’t improve is most probably due to the fact they are not treating these coinfections which can be as bad if not worse than Lyme.  Bartonella and Babesia are two such pathogens that can knock you off your feet but require very different medications than Lyme meds.  This is simply never discussed.

My husband and I are two chronically infected patients that have improved vastly with extended antimicrobial treatment.  Without this treatment, I’m not sure either of us would be alive.  I know many others in this boat as well.  We don’t make the research papers because none of us fit the criteria to even enter a study:

These parameters that continue to be used will continue to give a preconceived outcome: no chronic/persistent infection.  It’s circular reasoning of the worst kind that hasn’t budged in over 40 years.

Compare this to Dr. Lee Merritt’s informative talk where she describes experiments done on prisoners in the 1900’s that would see them deliberately infected with the Spanish Flu.

The experiments would see some of the prisoners injected with infected lung tissue from sick or deceased patients, have infected tissue dropped in their eyes, and sprayed in the nose and mouth with infectious aerosols. Others would see mucus taken from critically ill patients and put it into the noses and throats of prisoners. In other parts of the trials, experimenters would take the blood of the sick and inject it into the healthy, to see if it was spread through infectious microorganisms in the blood.

As well as the various fluid exchanges mentioned above, a further part of the experiments saw ten healthy prisoners taken into a hospital for patients who were dying of the disease. There, they were asked to stand over the sick and dying, lean over their faces and breathe in heavily while they exhaled. Just to be sure of exposure, the flu patients would cough into the face and mouths of the prisoners.

Ponder this for a moment.  
I mean, what is the likelihood?
Yet, despite this fact, we are told that the Spanish Flu is the most deadly virus on the planet.
According to many experts, this lack of proof of viral infectivity is a big deal but has resulted in a massively lucrative “vaccination” program that only worsens with time – now forcing people to concede to these injections or lose their jobs.
Meanwhile, back in Lymeland, lack of definitive proof stops the show.  Experts claim, “If we can’t see it, smell it, touch it, it doesn’t exist.” 
Anyone with half a brain would see this comparison and acknowledge that something is truly rotten in Denmark.

******

Alan MacDonald, MD: The Connection Between Syphilis, Lyme & Dementia

https://rumble.com/v2xnzl8-alan-macdonald-md-the-connection-between-syphilis-lyme-and-dementia.html  Video Here (Approx. 1 hour 15 min)

Alan MacDonald, MD, The Connection Between Syphilis, Lyme, & Dementia

Source: Lillian McDermott Radio Show/Classroom
https://www.bitchute.com/video/3faoq7wH7Mw0/

June, 2023

A pathologist’s job is to identify the cause of death of an individual. For Alan MacDonald, MD, his journey has led him to discover more than any of us could have imagined. Because this is the first time in 11 years that we have had a pathologist in The Classroom, I will just say, I am grateful to Dr. MacDonald for sharing the connection between syphilis, Lyme, and dementia, in The Classroom!

For more:

Tick-Borne Myopericarditis With Positive Anaplasma, Lyme, and EBV Serology

https://www.cureus.com/articles/163816-tick-borne-myopericarditis-with-positive-anaplasma-lyme-and-epstein-barr-virus-ebv-serology-a-case-report#!/

Tick-Borne Myopericarditis With Positive Anaplasma, Lyme, and Epstein Barr Virus (EBV) Serology: A Case Report

Hassaan Arshad • Bashar Oudah • Aliaa Mousa • Tigran Kakhktsyan • Mohammad Abu-Abaa • Ashish Agarwal

Published: June 14, 2023

DOI: 10.7759/cureus.40440 

Peer-Reviewed

Cite this article as: Arshad H, Oudah B, Mousa A, et al. (June 14, 2023) Tick-Borne Myopericarditis With Positive Anaplasma, Lyme, and Epstein Barr Virus (EBV) Serology: A Case Report. Cureus 15(6): e40440. doi:10.7759/cureus.4044

Abstract

Myopericarditis has been reported only rarely in those with anaplasmosis and is typically difficult to diagnose. Lyme carditis can also be difficult to diagnose as it is relatively rare but potentially fatal and usually has nonspecific manifestations. We are presenting a 61-year-old male patient who presented in New Jersey, United States with unremitting fever, chills, and myalgia for two weeks along with nausea, vomiting, and diarrhea. Investigations were suggestive of perimyocarditis as was indicated by diffuse ST segment elevation on electrocardiography (EKG) with the presence of small pericardial effusion on echocardiography. A mild troponin leakage was also seen. This progressed to septic shock that required vasopressor therapy. Further history-taking revealed recent tick exposure and prompted empirical initiation of doxycycline. This proved to be successful with fever defervescence and clinical improvement. Serological tests confirmed both acute Lyme and anaplasma infections along with positive serology of Epstein Barr virus (EBV). This case highlights an uncommon presentation of carditis in acute Lyme and anaplasma infections with the associated false-positive serology of EBV. 

_________________

**Comment**

Again, not uncommon, just uncommonly reported.  How many cases must be reported before it is no longer rare?  It is also known in Lymeland that those with concurrent infections have more severe cases requiring longer treatment with many medications.

Yet sadly, the authors state:

“Both anaplasma and Lyme carditis usually have a good prognosis and can resolve spontaneously without intervention.”

Are you for real?

It’s statements like these that continue to undermine any forward progress as it supports an antiquated belief that these are simple nuisance illnesses that will go away on their own. Recent case studies have shown that chronically infected patients were helped with combo treatments given for a longer period of time.

Another glaring problem: not seeing a tick or rash. How many patients have similar presentations but because they don’t recall a tick bite they are misdiagnosed with something else?

For more:

Paralyzed by Lyme, They Were Helped With Combo Treatments

https://www.lymedisease.org/remission-from-lyme-paralysis/

Paralyzed by Lyme, they were helped with combo treatments

By Lonnie Marcum

July 19, 2023

A new study from France looks at the use of combination antibiotics and anti-parasitic treatments in patients with limb paralysis as a result of tick-borne infections, including Lyme disease.

Approximately 70% of the patients in this study showed complete remission of symptoms after long-term treatment—a statistic that lines up with the MyLymeData treatment study.

The paper entitled, Complete Remission in Paralytic Late Tick-Borne Neurological Disease Comprising Mixed Involvement of Borrelia, Babesia, Anaplasma, and Bartonella: Use of Long-Term Treatments with Antibiotics and Antiparasitics in a Series of 10 Cases was published in Antibiotics.

The inclusion criteria for this study required a score of 4 or more on the Kurtzke EDSS disability scale; positive blood tests for one or more tick-borne pathogen (including Borrelia burgdorferi, Babesia, Anaplasma or Bartonella); and chronic general symptoms including fatigue, pain, and cognitive deficits lasting six or more months.

The Extended Disability Status Scale (EDSSis a tool commonly used to quantify the level of disability in patients with multiple sclerosis. The EDSS grades six bodily functions, including visual, brain, bowel/bladder and sensory functions, as well as the patients’ ability to walk and take care of themselves.

All 10 of the patients that qualified for this study were severely disabled with partial or complete paralysis in at least one limb. Five of the 10 required a wheelchair for mobility, and four required assistive devices like walking sticks to get around.

Complete remission for 7 out of 10

Following extended treatment, seven out of 10 patients (70%) showed complete remission of symptoms. Among the nine patients with positive Borrelia serology (along with co-infections), 77% obtained complete remission.

The treatment administered varied according to the patient’s infection profile. The majority of the patients received repeated oral regimens of azithromycin-doxycycline and azithromycin-doxycycline-rifampin plus a minimum of three 35-day cycles of IV ceftriaxone. The eight patients co-infected with Babesia (a parasite) were also administered anti-parasitic cycles of atovaquone–azithromycin. The mean duration of treatment was 20 months +/- 6 months. (Trouillas 2023)

Historically, patients with late-stage Lyme disease have poor outcomes to single regimens of 10-day IV ceftriaxone. (I’ve previously written about brain inflammation, and small fiber neuropathy found in patients with continuing symptoms after short-term treatment for Lyme disease.)

And we have decades of strong evidence that under-treatment with single antibiotics is consistent with persistent infection in animal studies. (Embers 2012)

Two weeks isn’t enough

As far back as 1990, Dr. Allen Steere co-authored a paper on patients with persistent late-stage neurological Lyme disease.

In this paper Dr. Steere and his co-authors state:

Months to years after the initial infection with B. burgdorferi, patients with Lyme disease may have chronic encephalopathy, polyneuropathy, or less commonly, leukoencephalitis. These chronic neurologic abnormalities usually improve with antibiotic therapy.

Six months after a two-week course of intravenous ceftriaxone (2 g daily), 17 patients (63 percent) had improvement, 6 (22 percent) had improvement but then relapsed, and 4 (15 percent) had no change in their condition.

Six months after treatment, more than one third of the patients either had relapsed or were no better. In addition, more than half had previously received antibiotic therapy thought to be appropriate for their stage of disease and still had progression of the illness. The likely reason for relapse is failure to eradicate the spirochete completely with a two-week course of intravenous ceftriaxone therapy. (Logigian 1990)

MyLymeData

In fact, the MyLymeData study validates that longer antibiotic treatment durationare associated with moderate to a very great deal of improvement. (Johnson 2020)

MyLymeData is currently the largest observational study of patients using real-world data to analyze the response to treatment of chronic Lyme disease patients. The majority of patients (57%) reported treatment durations of four or more months,

The results of this new French study demonstrate the importance of clinicians being able to continue treatment until a patient’s symptoms have resolved. It is clear, at least in this study, that the presence of co-infections greatly compounds one’s disease progress and treatment options.

LymeSci is written by Lonnie Marcum, a Licensed Physical Therapist and mother of a daughter with Lyme. She served two terms on a subcommittee of the federal Tick-Borne Disease Working Group. Follow her on Twitter: @LonnieRhea  Email her at: lmarcum@lymedisease.org.

References

Embers ME, Barthold SW, Borda JT, Bowers L, Doyle L, Hodzic E, et al. Persistence of Borrelia burgdorferi in Rhesus Macaques following Antibiotic Treatment of Disseminated Infection. PLoS ONE. 2012;7(1):e29914. Available at: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0029914.

 Johnson, L.; Shapiro, M.; Stricker, R.B.; Vendrow, J.; Haddock, J.; Needell, D. Antibiotic Treatment Response in Chronic Lyme Disease: Why Do Some Patients Improve While Others Do Not? Healthcare 2020, 8, 383. https://www.mdpi.com/2227-9032/8/4/383

Logigian EL, Kaplan RF, Steere AC. Chronic neurologic manifestations of Lyme disease. N Engl J Med. 1990 Nov 22;323(21):1438-44. doi: 10.1056/NEJM199011223232102. PMID: 2172819.

Trouillas P, Franck M. Complete Remission in Paralytic Late Tick-Borne Neurological Disease Comprising Mixed Involvement of Borrelia, Babesia, Anaplasma, and Bartonella: Use of Long-Term Treatments with Antibiotics and Antiparasitics in a Series of 10 Cases. Antibiotics. 2023; 12(6):1021. https://doi.org/10.3390/antibiotics12061021

_________________

For more:

Lyme Disease & the Pursuit of a Clinical Cure

https://www.frontiersin.org/articles/10.3389/fmed.2023.1183344/full

REVIEW article

Front. Med., 24 May 2023
Sec. Infectious Diseases: Pathogenesis and Therapy
Volume 10 – 2023 | https://doi.org/10.3389/fmed.2023.1183344

Lyme disease and the pursuit of a clinical cure

  • Division of Immunology, Tulane National Primate Research Center, Tulane University Health Sciences, Covington, LA, United States

Lyme disease, caused by the spirochete Borrelia burgdorferi, is the most common vector-borne illness in the United States. Many aspects of the disease are still topics of controversy within the scientific and medical communities. One particular point of debate is the etiology behind antibiotic treatment failure of a significant portion (10–30%) of Lyme disease patients. The condition in which patients with Lyme disease continue to experience a variety of symptoms months to years after the recommended antibiotic treatment is most recently referred to in the literature as post treatment Lyme disease syndrome (PTLDS) or just simply post treatment Lyme disease (PTLD). The most commonly proposed mechanisms behind treatment failure include host autoimmune responses, long-term sequelae from the initial Borrelia infection, and persistence of the spirochete. The aims of this review will focus on the in vitro, in vivo, and clinical evidence that either validates or challenges these mechanisms, particularly with regard to the role of the immune response in disease and resolution of the infection. Next generation treatments and research into identifying biomarkers to predict treatment responses and outcomes for Lyme disease patients are also discussed. It is essential that definitions and guidelines for Lyme disease evolve with the research to translate diagnostic and therapeutic advances to patient care.

_________________

Translation:  TIME FOR CHANGE!

Thankfully the study authors point out the following:
  • Without intervention, Bb establishes a persistent/chronic infection in both its reservoir and non-reservoir hosts.  
  • Controversy regarding chronic infection revolves around whether Bb can persist after antibiotics and whether they are capable of causing the symptoms patients experience.
  • There are many bacterial species associated with persistent infections in humans including: Mycobacterium tuberculosisPseudomonas aeruginosaEscherichia coliStaphylococcus aureus, and B. burgdorferi (109).
  • Bacterial tolerance is different from resistance in that bacteria are not actively growing in the presence of the antibiotic and there is no heritable genetic change in the persistent bacteria’s genome (110111).
  • The stress response and other mechanisms allow bacteria, including Borrelia, to survive lethal conditions such as limited nutrients, extreme pH levels, and the presence of certain antibiotics.
  • Drug-induced bacterial persisters show a biphasic killing curve and the regrown persister cells have the same minimum inhibitory concentration (MIC) to the administered antibiotic as the original population but a higher minimum bactericidal concentration (MBC) (112).
  • Several independent studies have demonstrated that Bb can form drug-tolerant persister cell in vitro.
  • In vivo studies of Bb antibiotic persistence often use different parameters that can make comparisons between two or more studies difficult.
  • It is likely that lack of consensus of definitions and diagnosis lead to the treatment controversy.
  • Despite treatment controversy, a biostatistical review of the literature found that retreatment of LD with antibiotics may be beneficial in certain cases (163).
  • Since research for PTLD revolves around autoimmunity, immune-mediated factors, and/or persistent infection, most drugs fit into one of three categories: immune therapies, pathogen specific inhibitors, or antibiotics.
  • Studies screening drug libraries have revealed:
    • disulfiram has demonstrated borreliacidal activity both in vitro and in vivo (174176)
    • vancomycin may have efficacy against stationary Bb based upon cultures and evaluation in SCID mice (177)
    • hygromycin A has shown efficacy against Bb, without disturbing the gut microbiome like so many broad-spectrum antibiotics, in vitro and in an in vivo mouse assay, but it’s use in preventing persistent infections was not determined (178)
    • drug combinations such as daptomycin or artemisinin, cefoperazone, and doxycycline as well as the combination sulfachlorpyridazine, daptomycin, and doxycycline have shown evidence of in vitro activity against Bb persisters and round bodied forms (117172). Azlocillin and cefotaxime are effective in in vitro killing against Bb persisters induced by doxycycline, which appear to be more tolerant to other antibiotics (179).
    • daptomycin or daunomycin, doxycycline, and cefuroxime have had success in sterilizing in vitro Bb biofilm-like microcolonies (180181).
    • dapsone, used in treatment of leprosy, has had success when combined with other antibiotics in killing biofilm-like Bb (182), and dapsone has had positive effects in a small PTLD and co-infection clinical study (183).
    • oregano, cinnamon bark, clove, and various flowers, grasses, and berries, as well as natural compounds such as those found in bee venom and its component melittin have demonstrated potential in vitro growth inhibition against Bb and its various forms (184188) but need further research to determine the safety and efficacy of, and the composition and activity of the exact compounds found.
  • Curative treatment during early LD stages is a key to solving the current PTLD public health problem.
  • It is likely that more than one mechanism is involved in antibiotic treatment failure that leads to PTLD.
  • The current treatment guidelines are dependent upon the immune system’s ability to clear persistent spirochetes and conditional to the surviving spirochetes being non-viable and not enough to sustain a prolonged immune response.
  • In order to make PTLD a thing of the past, personalized medicine is required as well as the need to evolve and progress with scientific discoveries and innovations.